Tacrolimus (FK 506) Overdose: A Report of Five Cases

References

• McCauley J., Fung J., Jain A., Todo S., Starzl T. E. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990; 22: 17S–20S
   PubMed Web of Science ®Google Scholar
• Thomson A. W. FK 506: Profile of an important new immunosuppressant. Transplant Rev 1990; 4: 1–13
   Google Scholar
• Goto T., Kino T., Hatanaka H., et al. Discovery of FK 506, a novel immunosuppressant isolated from Streptomyces tsukubaensis. Transplant Proc 1987; 19: 4S–8S
   PubMed Web of Science ®Google Scholar
• Fung J., Alessiani M., Abu‐Elmagd K., et al. Adverse effects associated with the use of FK 506. Transplant Proc 1991; 23: 3105–3108
   PubMed Web of Science ®Google Scholar
• Jain A. B., Fung R., Venkataramanan S., Todo S., Alessiani M., Starzl T. E. FK 506 dosage in human organ transplantation. Transplant Proc 1990; 22: 23–24
   PubMed Web of Science ®Google Scholar
• Venkataramanan R., Jain A., Warty V. S., et al. Pharmacokinetics of FK 506 in transplant patients. Transplant Proc 1991; 23: 2736–2740
   PubMed Web of Science ®Google Scholar
• Hooks M. A. Tacrolimus, a new immunosuppressant‐a review of the literature. Ann Pharmacother 1994; 28: 501–511
   PubMed Web of Science ®Google Scholar
• Jusko W. J., Piekoszewski W., Klintmalm G. B., et al. Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 1995; 57: 281–290
   PubMed Web of Science ®Google Scholar
• Sattler M., Guengerich F. P., Yun C. H., Christians U., Sewing K. F. Cytochrome P‐450 3A enzymes are responsible for biotransformation of FK 506 and rapamycin in man and rat. Drug Metab Dispos 1992; 20: 753–761
   PubMed Web of Science ®Google Scholar
• Yasuhara M., Hashida T., Toraguchi M., et al. Pharmacokinetics and pharmacodynamics of FK 506 in pediatric patients receiving living‐related donor liver transplantations. Transplant Proc 1995; 27: 1108–1110
   PubMed Web of Science ®Google Scholar
• Assan R., Fredji G., Larger E., Feutren G., Bismuth H. FK 506/fluconazole interaction enhances FK 506 nephrotoxicity. Diabete Metab 1994; 20: 49–52
   PubMed Web of Science ®Google Scholar
• Schwartz M., Holst B., Facklam D., Buell D. FK 506 in liver transplantation: correlation of whole blood levels with efficacy and toxicity. Transplant Proc 1995; 27: 1107
   PubMed Web of Science ®Google Scholar
• Warty V., Zuckerman S., Venkataramanan R., et al. Tacrolimus analysis: a comparison of different methods and matrices. Ther Drug Monit 1995; 17: 159–167
   PubMed Web of Science ®Google Scholar
• Alessiani M., Cillo U., Fung J. J., et al. Adverse effects of FK 506 overdosage after river transplantation. Transplant Proc 1993; 25: 628–634
   PubMed Web of Science ®Google Scholar
• Atkinson P., Joubert G., Barron A., et al. Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients. Lancet 1995; 345: 894–896
   PubMed Web of Science ®Google Scholar
• Hibi S., Misawa A., Tamai M., et al. Severe rhabdomyolysis associated with tacrolimus. Lancet 1995; 346: 702
   PubMed Web of Science ®Google Scholar
• Dollinger M. M., Plevris J. N., Chauhan A., MacGilchrist A. J., Finlayson M. D., Hayes P. C. Tacrolimus and cardiotoxicity in adult liver transplant recipients. Lancet 1995; 346: 507
   PubMed Web of Science ®Google Scholar
• Fisher A., Schwartz M., Mor E., et al. Gastrointestinal toxicity associated with FK 506 in liver transplant recipients. Transplant Proc 1994; 26: 3106–3107
   PubMed Web of Science ®Google Scholar
• Fisher A., Mor A., Hytiroglou P., et al. FK 506 hepatoxicity in liver allograft recipients. Transplantation 1995; 59: 1631–1632
   PubMed Web of Science ®Google Scholar
• Platz K. P., Mueller A. R., Blumhardt G. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK 506. Transplantation 1994; 58: 170–178
   PubMed Web of Science ®Google Scholar
• Porayko M. K., Textor S. C., Krom R. A., et al. Nephrotoxic effects of primary immunosuppression with FK 506 and cyclosporine regimens after liver transplantation. Mayo Clin Proc 1994; 69: 105–111
   PubMed Web of Science ®Google Scholar
• Winkler M., Jost U., Ring B., Gubernatis G., Wonigeit K., Pichlmayr R. Association of elevated FK 506 plasma levels with nephrotoxicity in liver‐grafted patients. Transplant Proc 1991; 23: 3153–3155
   PubMed Web of Science ®Google Scholar
• Sumpio B. E., Phan S. Nephrotoxic potential of FK 506. Transplant Proc 1991; 23: 2789–2790
   PubMed Web of Science ®Google Scholar
• Nielson F. T., Leyssac P. P., Kemp E., Starklint H., Dieperink H. Nephrotoxicity of FK 506: a preliminary study on comparative aspects of FK 506 and cyclosporine nephrotoxicity. Transplant Proc 1994; 26: 3104–3105
   PubMed Web of Science ®Google Scholar
• Andoh T. F., Brudmann E. A., Lindsely J., Houghton D. C., Bennett W. M. Functional and structural characteristics of experimental FK 506 nephrotoxicity. Clin Exp Pharmacol Physiol 1995; 22: 646–654
   PubMed Web of Science ®Google Scholar
• Wijdicks E. F., Wiesner R. H., Dahlke L. J., Drom R. A. FK 506‐induced neurotoxicity in liver transplantation. Ann Neurol 1994; 35: 498–501
   PubMed Web of Science ®Google Scholar
• Bronster D. J., Yonover P., Stein J., Scelsa S. N., Miller C. M., Sheiner P. A. Demyelinating sensorimotor polyneuropathy after administration of FK 506. Transplantation 1995; 59: 1066–1068
   PubMed Web of Science ®Google Scholar
• Ayres R. C., Dousset B., Wixon S., Buckels J. A., McMaster P., Mayer A. D. Peripheral neurotoxicity with tacrolimus. Lancet 1994; 343: 862–863
   PubMed Web of Science ®Google Scholar